De Leo Vincenzo, Cagnacci Angelo, Cappelli Valentina, Biasioli Anna, Leonardi Deborah, Seracchioli Renato
Unit of Obstetrics and Gynecology, Department of Molecular Medicine and Development, Università degli Studi, Siena, Italy -
Unit of Obstetrics and Gynecology, Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy.
Minerva Ginecol. 2019 Jun;71(3):191-195. doi: 10.23736/S0026-4784.19.04384-3. Epub 2019 Jan 28.
Dysmenorrhea and chronic pelvic pain occur in a significantly higher percentage in women with endometriosis; this benign condition has an incidence ranging from 5% to 10% in the general population, while 35% to 50% of infertile women are affected. Treatment of the symptoms demands integrated approaches with the use of anti-inflammatory substances or drugs and lifestyle changes, including attention to diet. The use of traditional anti-inflammatory drugs over the long term is not very successful because of the fear of side effects so they are almost always used with a short-term formula of 7-10 days when the woman's general condition becomes difficult to bear. In recent years, particular attention has been paid to natural substances with recognized anti-inflammatory activities that, associated with one another, are able to synergize individual actions. A nutraceutical containing substances capable of fighting chronic pelvic pain has recently been put on the market. The possible action mechanism derives from a synergy of action between alpha-lipoic acid, palmitoiletanolamide (PEA) and myrrh (Pelvinox, Laborest Italia srl, Nerviano, Milan, Italy), whose action is so effective that it is able to replace the use of anti-inflammatory drugs. The aim of the study was to evaluate the effect of these active ingredients in women with endometriosis and chronic pelvic pain.
This multicenter study saw the recruitment of 60 women (divided between the three centers participating in the study, Siena, Bologna and Udine) aged between 20 and 39 suffering from endometriosis (ovarian) and chronic pelvic pain. All the women took one nutraceutical (Pelvinox) at a dose of two tablets per day for 6 months.
The results showed a significant reduction in pain symptoms as regards dyspareunia, dysmenorrhea and chronic pelvic pain, while there was no change in the mean diameter of the endometriosis cysts.
In light of the above, it is believed that substances such as alpha-lipoic acid, PEA and myrrh may play a very important role in this type of patient in the treatment of individual symptoms.
子宫内膜异位症女性中痛经和慢性盆腔疼痛的发生率显著更高；这种良性疾病在普通人群中的发病率为5%至10%，而35%至50%的不孕女性受其影响。症状的治疗需要综合方法，包括使用抗炎物质或药物以及改变生活方式，包括注意饮食。由于担心副作用，长期使用传统抗炎药物效果不佳，因此几乎总是在女性总体状况难以忍受时采用7至10天的短期用药方案。近年来，人们特别关注具有公认抗炎活性的天然物质，这些物质相互关联，能够协同发挥各自的作用。最近，一种含有能够对抗慢性盆腔疼痛物质的营养保健品已投放市场。其可能的作用机制源于α-硫辛酸、棕榈酰乙醇酰胺（PEA）和没药（Pelvinox，意大利拉博雷斯特公司，米兰内尔维阿诺）之间的协同作用，其作用非常有效，能够替代抗炎药物的使用。本研究的目的是评估这些活性成分对患有子宫内膜异位症和慢性盆腔疼痛女性的影响。
这项多中心研究招募了60名年龄在20至39岁之间、患有（卵巢型）子宫内膜异位症和慢性盆腔疼痛的女性（分布在参与研究的三个中心，锡耶纳、博洛尼亚和乌迪内）。所有女性每天服用两片营养保健品（Pelvinox），持续6个月。
结果显示，性交困难、痛经和慢性盆腔疼痛的疼痛症状显著减轻，而子宫内膜异位症囊肿的平均直径没有变化。
鉴于上述情况，据信α-硫辛酸、PEA和没药等物质在这类患者的个体症状治疗中可能发挥非常重要的作用。
